Novelty is not readiness
A rare mechanism can score 5/5 for novelty and still be source-backed only. Novelty helps decide where to explore; evidence decides what can be promised.
Evidence-backed commercial inventory
Everything we could sell—without pretending everything is ready.
Owned platforms, composed suites, tenant apps, every current FoxFlow package and crate, plus original-source repository candidates. Forks, upstream mirrors, and explicitly excluded products stay out. Compare customer value, novelty, evidence, commercial priority, and a testable reseller price band.
Pricing is a commercialization recommendation, not a quote. Source presence is not deployment, security, compliance, or market proof.
—Total indexed records
—Launchable platform candidates
—Composed suites
—Tenant apps
—Packages + Rust crates
—Owner repositories triaged
Commercial lanes
Click a lane to filter the complete index. A lead offer still needs a scoped demo and quote gate.
Best first conversations
Highest commercial-priority source-backed offers. This is a sequencing recommendation, not a readiness claim.
The complete reseller index
Search source names, buyer outcomes, paths, packages, crates, platforms, and product hypotheses.
| Product / outcome | Level / evidence | Family | Value | Novelty | Readiness | Commercial lane | Setup / implementation | Recurring |
|---|---|---|---|---|---|---|---|---|
| Loading the complete source inventory… | ||||||||
—
How to use the numbers
The scoring system makes commercial judgment inspectable instead of hiding it in a “recommended” badge.
Price the outcome and the risk
Regulated health, lending, payments, identity, and security work carries a 1.4–2.5× scope multiplier. Usage-heavy voice, models, data, and trading need metered overages.
Use a quote gate
Define buyer, volume, dependencies, deployment proof, support, compliance, restore, and margin before issuing a firm quote. Read the full rubric.